The cost of Soliris (eculizumab), a drug known for its high price, is expected to drop significantly with the introduction of its biosimilar.

The original Soliris will also cut its price by 30% in line with the expansion of its reimbursement benefit to cover neuromyelitis optica, to compete with its biosimilars.

According to industry sources on the 22nd, Samsung Bioepis' Soliris biosimilar ‘Episcli Inj’ will be reimbursed from April.

The upper limit will be set at KRW 2,514,858 per vial. This is only 48.8% of the current upper limit set for Soliris, which is set at KRW 5,132,364.

The 1-year drug cost of Episcli Inj is also KRW 271 million, half the cost o